Rays of Belief Sets Sep 1 IPO to Fund 319-Centre Neurodevelopmental Care Expansion Across India

The Quick Take

• Rays of Belief Ltd, the operator of Mom's Belief neurodevelopmental care centres, will launch its IPO on September 1, 2026, with the issue open through September 3 and anchor investor bidding on August 31.
• IPO proceeds will fund an ambitious expansion to 319 new centres across India by FY2029, targeting neurodevelopmental care in Tier-II and Tier-III cities where services are severely underserved.
• The company has demonstrated impressive revenue growth heading into the listing, positioning the IPO as the first pure-play neurodevelopmental care listing on Indian public markets.

Rays of Belief's listing represents a niche healthcare category making its debut on Indian public markets at a time when specialty healthcare IPOs are commanding premium multiples based on growth rate and total addressable market arguments rather than near-term earnings. Neurodevelopmental care—serving children and adults with conditions including autism spectrum disorder, ADHD, cerebral palsy, and developmental delays—is a sector with enormous unmet demand in India, where the combination of limited specialist availability, stigma-related barriers to diagnosis, and geographic concentration of services in metropolitan areas has left the vast majority of the target population without access to structured therapeutic programmes.

The expansion to 319 new centres by FY2029 is the core investment thesis driver. At the current centre count, Rays of Belief operates at a scale that is commercially validated but well below the network density required to address India's estimated neurodevelopmental care gap in a meaningful way. The planned expansion into Tier-II and Tier-III cities is both a market opportunity and an operational risk: lower population density in these markets means slower centre ramp-up and higher marketing costs per enrolled patient, while labour market depth for qualified therapists and educators is shallower outside major metropolitan areas. Execution quality on the expansion will determine whether the IPO multiple is sustained post-listing.

The investor demand signal from anchor investors on August 31 will be the most informative data point before retail subscription opens. In Indian specialty healthcare IPOs, anchor quality—particularly the presence of domestic mutual funds and global long-only institutions—tends to correlate strongly with oversubscription rates in the QIB tranche. Retail and high-net-worth investor participation is expected to be driven by the social impact narrative and the novelty premium of the first neurodevelopmental care public listing, but those tranches are volatile and not a reliable indicator of sustainable post-listing demand. The IPO's long-term performance will hinge on whether FY2027 and FY2028 centre openings proceed on schedule.

Synthesized from 2 sources.